SG11201502605PA - Crystalline forms of a factor xia inhibitor - Google Patents

Crystalline forms of a factor xia inhibitor

Info

Publication number: SG11201502605PA
Authority: SG; Singapore
Prior art keywords: crystalline forms; factor xia; xia inhibitor; inhibitor; factor
Prior art date: 2012-10-12

Application number

SG11201502605PA

Inventor

Marta Dabros

Chenkou Wei

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-12

Filing date

2013-10-11

Publication date

2015-05-28

2013-10-11 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2015-05-28 Publication of SG11201502605PA publication Critical patent/SG11201502605PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)

SG11201502605PA 2012-10-12 2013-10-11 Crystalline forms of a factor xia inhibitor SG11201502605PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261712850P	2012-10-12	2012-10-12
PCT/US2013/064423 WO2014059203A1 (en)	2012-10-12	2013-10-11	Crystalline forms of a factor xia inhibitor

Publications (1)

Publication Number	Publication Date
SG11201502605PA true SG11201502605PA (en)	2015-05-28

Family

ID=49474724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201502605PA SG11201502605PA (en)	2012-10-12	2013-10-11	Crystalline forms of a factor xia inhibitor

Country Status (34)

Country	Link
US (1)	US9920034B2 (en)
EP (1)	EP2906551B1 (en)
JP (1)	JP6154473B2 (en)
KR (1)	KR102143257B1 (en)
CN (1)	CN104837833B (en)
AU (1)	AU2013329125B2 (en)
BR (1)	BR112015007937A2 (en)
CA (1)	CA2888100A1 (en)
CL (1)	CL2015000916A1 (en)
CO (1)	CO7350621A2 (en)
CY (1)	CY1120238T1 (en)
DK (1)	DK2906551T3 (en)
EA (1)	EA032092B1 (en)
ES (1)	ES2668318T3 (en)
HR (1)	HRP20180465T1 (en)
HU (1)	HUE038272T2 (en)
IL (1)	IL238089B (en)
LT (1)	LT2906551T (en)
MA (1)	MA38071B1 (en)
MX (1)	MX351848B (en)
MY (1)	MY173058A (en)
NO (1)	NO2819265T3 (en)
NZ (1)	NZ707990A (en)
PE (1)	PE20150639A1 (en)
PH (1)	PH12015500678A1 (en)
PL (1)	PL2906551T3 (en)
PT (1)	PT2906551T (en)
RS (1)	RS57039B1 (en)
SG (1)	SG11201502605PA (en)
SI (1)	SI2906551T1 (en)
SM (1)	SMT201800262T1 (en)
TR (1)	TR201807316T4 (en)
WO (1)	WO2014059203A1 (en)
ZA (1)	ZA201503238B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201311689A (en)	2011-08-05	2013-03-16	必治妥美雅史谷比公司	Novel macrocyclic compounds as factor XIA inhibitors
TW201319068A (en)	2011-08-05	2013-05-16	必治妥美雅史谷比公司	Cyclic P1 linkers as factor XIa inhibitors
PL2766346T3 (en)	2011-10-14	2017-09-29	Bristol-Myers Squibb Company	Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906541B1 (en)	2012-10-12	2017-11-22	Bristol-Myers Squibb Company	Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9315519B2 (en)	2012-10-12	2016-04-19	Bristol-Myers Squibb Company	Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
JP6479763B2 (en)	2013-03-25	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors
ES2687498T3 (en)	2014-01-31	2018-10-25	Bristol-Myers Squibb Company	Macrocycles with heterocyclic P2 ¿groups as inhibitors of factor XIa
NO2760821T3 (en)	2014-01-31	2018-03-10
ES2714283T3 (en)	2014-09-04	2019-05-28	Bristol Myers Squibb Co	Macrocycles of diamide that are inhibitors of FXIa
US9453018B2 (en)	2014-10-01	2016-09-27	Bristol-Myers Squibb Company	Pyrimidinones as factor XIa inhibitors
US10160750B2 (en)	2015-06-19	2018-12-25	Bristol-Myers Squibb Company	Diamide macrocycles as factor XIa inhibitors
CN107922393A (en)	2015-07-29	2018-04-17	百时美施贵宝公司	A New Macrocycle of Factor XIA Carrying a Non-aromatic P2, Group
CN107849026B (en)	2015-07-29	2021-01-01	百时美施贵宝公司	Factor XIA macrocycle inhibitors carrying alkyl or cycloalkyl P2' moieties
CN106496249B (en) *	2015-09-07	2019-12-13	江苏恒瑞医药股份有限公司	Oxazoloindole derivative, preparation method and medical application thereof
WO2017074833A1 (en)	2015-10-29	2017-05-04	Merck Sharp & Dohme Corp.	Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
WO2018039094A1 (en)	2016-08-22	2018-03-01	Merck Sharp & Dohme Corp.	Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN109867660A (en) *	2017-12-01	2019-06-11	四川科伦博泰生物医药股份有限公司	Tetrahydroisoquinoline amide compound and its medicinal usage containing quaternary ammonium ion
CN111655686B (en)	2018-03-28	2024-02-09	四川科伦博泰生物医药股份有限公司	Tetrahydroisoquinoline derivatives and their preparation methods and uses

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR7155E (en)	1906-03-16	1907-05-23	Rene Gabriel Poncet	Rotary dryer
FR1525186A (en)	1967-03-29	1968-05-17	Roussel Uclaf	New penicillins and method of preparation
ATA937274A (en)	1973-12-17	1978-02-15	Thomae Gmbh Dr K	PROCESS FOR PRODUCING NEW ARALIPHATIC KETONES
DE4034829A1 (en)	1990-11-02	1992-05-07	Merck Patent Gmbh	CYCLOPEPTIDE
JP3190431B2 (en)	1991-07-01	2001-07-23	三菱化学株式会社	Ketone derivatives
GB9206757D0 (en)	1992-03-27	1992-05-13	Ferring Bv	Novel peptide receptor ligands
WO1996034010A2 (en)	1995-03-29	1996-10-31	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5624936A (en)	1995-03-29	1997-04-29	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5869682A (en)	1996-04-03	1999-02-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU717298B2 (en)	1996-04-03	2000-03-23	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
ID27002A (en)	1998-03-19	2001-02-22	Vertex Pharma	CASASAGE OBSERVERS
EE200000706A (en)	1998-05-26	2002-06-17	Warner-Lambert Company	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cell proliferation
US6307049B1 (en)	1998-09-30	2001-10-23	The Procter & Gamble Co.	Heterocyclic 2-substituted ketoamides
CN1332734A (en)	1999-01-02	2002-01-23	阿文蒂斯药物德国有限公司	Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity
EP1016663A1 (en)	1999-01-02	2000-07-05	Aventis Pharma Deutschland GmbH	Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
IL145771A0 (en)	1999-04-09	2002-07-25	Basf Ag	Low-molecular inhibitors of complement proteases
EP1125925A1 (en)	2000-02-15	2001-08-22	Applied Research Systems ARS Holding N.V.	Amine derivatives for the treatment of apoptosis
CN1244561C (en)	2000-05-11	2006-03-08	布里斯托尔-迈尔斯斯奎布公司	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SV2003000617A (en)	2000-08-31	2003-01-13	Lilly Co Eli	INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
AU2002322802A1 (en)	2001-07-27	2003-02-17	Merck And Co., Inc.	Thrombin inhibitors
US6649606B1 (en)	2001-11-09	2003-11-18	Bristol-Myers Squibb Co.	Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7138412B2 (en)	2003-03-11	2006-11-21	Bristol-Myers Squibb Company	Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en)	2003-04-16	2006-10-31	Bristol-Myers Squibb Company	Biarylmethyl indolines and indoles as antithromboembolic agents
JP2007501844A (en)	2003-08-08	2007-02-01	トランス　テック　ファーマ，インコーポレイテッド	Aryl and heteroaryl compounds, compositions and methods of use
US7417063B2 (en)	2004-04-13	2008-08-26	Bristol-Myers Squibb Company	Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en)	2004-06-15	2008-11-18	Bristol-Myers Squibb Company	Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en)	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
EP2457895A1 (en)	2004-07-12	2012-05-30	Idun Pharmaceuticals, Inc.	Tetrapeptide analogs
CN101137412B (en)	2005-01-13	2012-11-07	布里斯托尔-迈尔斯·斯奎布公司	Substituted biaryl compounds as factor xia inhibitors
US20060183771A1 (en)	2005-02-17	2006-08-17	Seiffert Dietmar A	Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
US20070112012A1 (en) *	2005-11-11	2007-05-17	Markus Boehringer	Carbocyclic fused cyclic amines
EP1966141A1 (en)	2005-12-14	2008-09-10	Brystol-Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
WO2007070816A2 (en)	2005-12-14	2007-06-21	Bristol-Myers Squibb Company	Thiophene derivatives as factor xia inhibitors
WO2007070826A1 (en)	2005-12-14	2007-06-21	Bristol-Myers Squibb Company	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20071132A1 (en)	2005-12-23	2007-12-14	Bristol Myers Squibb Co	MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
WO2008076805A2 (en)	2006-12-15	2008-06-26	Bristol-Myers Squibb Company	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (en)	2006-12-20	2008-12-18	Bristol Myers Squibb Co	MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
JP5318094B2 (en)	2007-06-13	2013-10-16	ブリストル−マイヤーズスクイブカンパニー	Dipeptide analogs as clotting factor inhibitors
CN102026996B (en)	2008-03-13	2015-01-07	百时美施贵宝公司	Pyridazine derivatives as factor XIA inhibitors
US8624040B2 (en)	2009-06-22	2014-01-07	Millennium Pharmaceuticals, Inc.	Substituted hydroxamic acids and uses thereof
US8513433B2 (en)	2009-07-02	2013-08-20	Angion Biomedica Corp.	Small molecule inhibitors of PARP activity
EP2462123B1 (en)	2009-08-04	2013-10-02	Merck Sharp & Dohme Corp.	4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
US8828983B2 (en)	2010-02-11	2014-09-09	Bristol-Myers Squibb Company	Macrocycles as factor XIa inhibitors
WO2013009527A2 (en)	2011-07-08	2013-01-17	Merck Sharp & Dohme Corp.	Factor ixa inhibitors
TW201319068A (en)	2011-08-05	2013-05-16	必治妥美雅史谷比公司	Cyclic P1 linkers as factor XIa inhibitors
TW201311689A (en)	2011-08-05	2013-03-16	必治妥美雅史谷比公司	Novel macrocyclic compounds as factor XIA inhibitors
IN2014CN02806A (en)	2011-10-14	2015-07-03	Bristol Myers Squibb Co
PL2766346T3 (en) *	2011-10-14	2017-09-29	Bristol-Myers Squibb Company	Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6033318B2 (en)	2011-10-14	2016-11-30	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
DK2794597T3 (en)	2011-12-21	2018-01-15	Ono Pharmaceutical Co	PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
US20140378474A1 (en)	2012-01-27	2014-12-25	Novartis Ag	5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (en)	2012-01-27	2014-12-03	Novartis AG	Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (en)	2012-02-08	2015-04-30	大日本住友製薬株式会社	Three substituted proline derivative
SI2847228T1 (en)	2012-05-10	2018-11-30	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
GB201209138D0 (en)	2012-05-24	2012-07-04	Ono Pharmaceutical Co	Compounds
WO2014014050A1 (en)	2012-07-19	2014-01-23	大日本住友製薬株式会社	1-(cycloalkyl-carbonyl)proline derivative
CA2880898A1 (en)	2012-08-03	2014-02-06	Bristol-Myers Squibb Company	Dihydropyridone p1 as factor xia inhibitors
US9409908B2 (en)	2012-08-03	2016-08-09	Bristol-Myers Squibb Company	Dihydropyridone p1 as factor XIa inhibitors
US9315519B2 (en)	2012-10-12	2016-04-19	Bristol-Myers Squibb Company	Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2906541B1 (en)	2012-10-12	2017-11-22	Bristol-Myers Squibb Company	Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2934538B1 (en)	2012-12-19	2021-03-31	Merck Sharp & Dohme Corp.	Factor ixa inhibitors
GB201300304D0 (en)	2013-01-08	2013-02-20	Kalvista Pharmaceuticals Ltd	Benzylamine derivatives
GB2510407A (en)	2013-02-04	2014-08-06	Kalvista Pharmaceuticals Ltd	Aqueous suspensions of kallikrein inhibitors for parenteral administration
JP6479763B2 (en)	2013-03-25	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors

2013
- 2013-10-11 EA EA201590548A patent/EA032092B1/en not_active IP Right Cessation
- 2013-10-11 PL PL13780287T patent/PL2906551T3/en unknown
- 2013-10-11 KR KR1020157011941A patent/KR102143257B1/en not_active Expired - Fee Related
- 2013-10-11 ES ES13780287.2T patent/ES2668318T3/en active Active
- 2013-10-11 EP EP13780287.2A patent/EP2906551B1/en active Active
- 2013-10-11 NZ NZ707990A patent/NZ707990A/en not_active IP Right Cessation
- 2013-10-11 JP JP2015536906A patent/JP6154473B2/en not_active Expired - Fee Related
- 2013-10-11 CA CA2888100A patent/CA2888100A1/en not_active Abandoned
- 2013-10-11 SI SI201330987T patent/SI2906551T1/en unknown
- 2013-10-11 MY MYPI2015701150A patent/MY173058A/en unknown
- 2013-10-11 WO PCT/US2013/064423 patent/WO2014059203A1/en not_active Ceased
- 2013-10-11 CN CN201380064797.5A patent/CN104837833B/en not_active Expired - Fee Related
- 2013-10-11 MX MX2015004328A patent/MX351848B/en active IP Right Grant
- 2013-10-11 DK DK13780287.2T patent/DK2906551T3/en active
- 2013-10-11 TR TR2018/07316T patent/TR201807316T4/en unknown
- 2013-10-11 SG SG11201502605PA patent/SG11201502605PA/en unknown
- 2013-10-11 LT LTEP13780287.2T patent/LT2906551T/en unknown
- 2013-10-11 AU AU2013329125A patent/AU2013329125B2/en not_active Ceased
- 2013-10-11 SM SM20180262T patent/SMT201800262T1/en unknown
- 2013-10-11 BR BR112015007937A patent/BR112015007937A2/en not_active Application Discontinuation
- 2013-10-11 US US14/434,507 patent/US9920034B2/en active Active
- 2013-10-11 PT PT137802872T patent/PT2906551T/en unknown
- 2013-10-11 RS RS20180328A patent/RS57039B1/en unknown
- 2013-10-11 PE PE2015000477A patent/PE20150639A1/en not_active Application Discontinuation
- 2013-10-11 HR HRP20180465TT patent/HRP20180465T1/en unknown
- 2013-10-11 HU HUE13780287A patent/HUE038272T2/en unknown
2014
- 2014-05-21 NO NO14169333A patent/NO2819265T3/no unknown
2015
- 2015-03-26 PH PH12015500678A patent/PH12015500678A1/en unknown
- 2015-04-01 IL IL238089A patent/IL238089B/en active IP Right Grant
- 2015-04-10 CL CL2015000916A patent/CL2015000916A1/en unknown
- 2015-05-07 MA MA38071A patent/MA38071B1/en unknown
- 2015-05-07 CO CO15104857A patent/CO7350621A2/en unknown
- 2015-05-11 ZA ZA2015/03238A patent/ZA201503238B/en unknown
2018
- 2018-05-18 CY CY20181100522T patent/CY1120238T1/en unknown

Also Published As

Publication number	Publication date
PL2906551T3 (en)	2018-07-31
CY1120238T1 (en)	2019-07-10
AU2013329125A1 (en)	2015-05-28
CO7350621A2 (en)	2015-08-10
JP2015533168A (en)	2015-11-19
BR112015007937A2 (en)	2017-07-04
EA032092B1 (en)	2019-04-30
NZ707990A (en)	2018-07-27
PH12015500678A1 (en)	2015-05-18
HUE038272T2 (en)	2018-10-29
CN104837833B (en)	2017-07-14
MA38071A1 (en)	2016-06-30
HRP20180465T1 (en)	2018-05-04
JP6154473B2 (en)	2017-06-28
SMT201800262T1 (en)	2018-07-17
PE20150639A1 (en)	2015-05-11
US9920034B2 (en)	2018-03-20
MX351848B (en)	2017-10-31
EP2906551B1 (en)	2018-02-28
EA201590548A1 (en)	2015-07-30
PT2906551T (en)	2018-05-10
TR201807316T4 (en)	2018-06-21
CN104837833A (en)	2015-08-12
MY173058A (en)	2019-12-23
HK1212333A1 (en)	2016-06-10
LT2906551T (en)	2018-04-25
DK2906551T3 (en)	2018-05-22
ZA201503238B (en)	2017-11-29
EP2906551A1 (en)	2015-08-19
KR20150065189A (en)	2015-06-12
AU2013329125B2 (en)	2017-03-30
CA2888100A1 (en)	2014-04-17
MX2015004328A (en)	2015-06-10
CL2015000916A1 (en)	2015-08-14
NO2819265T3 (en)	2018-07-28
WO2014059203A1 (en)	2014-04-17
RS57039B1 (en)	2018-05-31
IL238089B (en)	2019-03-31
KR102143257B1 (en)	2020-08-10
ES2668318T3 (en)	2018-05-17
MA38071B1 (en)	2017-01-31
SI2906551T1 (en)	2018-05-31
US20150266855A1 (en)	2015-09-24

Publication	Publication Date	Title
HUS2200030I1 (en)	2022-07-28	Crystalline forms of a prolyl hydroxylase inhibitor
ZA201503238B (en)	2017-11-29	Crystalline forms of a factor xia inhibitor
ZA201408141B (en)	2015-09-30	Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
PL2892889T3 (en)	2018-03-30	Inhibitor compounds
IL237011A0 (en)	2015-03-31	Dihydropyridone p1 as factor xia inhibitors
HRP20181751T1 (en)	2018-12-28	Crystalline forms of a prolyl hydroxylase inhibitor
LT2882734T (en)	2016-12-12	DIHYDROPYRIDONE AS FACTOR XIa INHIBITORS
PL2863918T3 (en)	2020-05-18	Salt crystals of a pde1 inhibitor
ZA201406238B (en)	2016-08-31	Crystalline form of a succinate salt
GB201211019D0 (en)	2012-08-01	Inhibitor compounds